Davide Bonazzi
Illustrator
From this contributor
Company on brink takes psilocybin to trial for fragile X syndrome
The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.
Company on brink takes psilocybin to trial for fragile X syndrome
Explore more from The Transmitter
The Transmitter’s favorite essays and columns of 2024
From sex differences in Alzheimer’s disease to enduring citation bias, experts weighed in on important scientific and practical issues in neuroscience.
The Transmitter’s favorite essays and columns of 2024
From sex differences in Alzheimer’s disease to enduring citation bias, experts weighed in on important scientific and practical issues in neuroscience.
Say what? The Transmitter’s top quotes of 2024
“We’ve cured mouse-heimer’s thousands of times...”—find out who said this to a Transmitter reporter, and read our other favorite quotes from the past year.
Say what? The Transmitter’s top quotes of 2024
“We’ve cured mouse-heimer’s thousands of times...”—find out who said this to a Transmitter reporter, and read our other favorite quotes from the past year.
The Transmitter’s favorite podcasts of 2024
Our picks include a deep dive into dopamine, the role of PKMzeta in memory, and studying the stomatogastric ganglion.
The Transmitter’s favorite podcasts of 2024
Our picks include a deep dive into dopamine, the role of PKMzeta in memory, and studying the stomatogastric ganglion.